The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies

Seminars in Hematology

Volumn 51, Issue 1, 2014, Pages 25-34

  Karlin, Lionel ^a   Coiffier, Bertrand ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALISERTIB; BELINOSTAT; BENDAMUSTINE; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CARMUSTINE; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DENILEUKIN DIFTITOX; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MOGAMULIZUMAB; PANOBINOSTAT; PRALATREXATE; PREDNISONE; ROMIDEPSIN; VINBLASTINE; VINCRISTINE; VINDESINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CUTANEOUS T CELL LYMPHOMA; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG WITHDRAWAL; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; PROGNOSIS; RECURRENCE;

EID: 84892945819     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.11.001     Document Type: Article

References (80)

1. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
2. Morton L.M., Wang S.S., Devesa S.S., Hartge P., Weisenburger D.D., Linet M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
3. Sonnen R., Schmidt W.P., Muller-Hermelink H.K., Schmitz N. The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005, 129:366-372.
4. Weisenburger D.D., Savage K.J., Harris N.L., et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood 2011, 117:3402-3408.
5. Foss F.M. Treatment strategies for peripheral T-cell lymphomas. Best Pract Res Clin Haematol 2013, 26:43-56.
6. Escalon M.P., Liu N.S., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 2005, 103:2091-2098.
7. Gressin R., Caulet-Maugendre S., Deconinck E., et al. Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010, 95:1350-1357.
8. Jerkeman M., Anderson H., Cavallin-Stahl E., et al. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial. Ann Oncol 1999, 10:1079-1086.
9. Schmitz N., Trumper L., Ziepert M., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010, 116:3418-3425.
10. Tilly H., Lepage E., Coiffier B., et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003, 102:4284-4289.
11. Yared J., Kimball A. The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat Rev 2013, 39:51-59.
12. Gisselbrecht C., Lepage E., Molina T., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472-2479.
13. Haioun C., Lepage E., Gisselbrecht C., et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000, 18:3025-3030.
14. Mounier N., Gisselbrecht C., Briere J., et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004, 15:1790-1797.
15. Rodriguez J., Conde E., Gutierrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652-657.
16. Rodriguez J., Conde E., Gutierrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007, 79:32-38.
17. Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
18. Mercadal S., Briones J., Xicoy B., et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958-963.
19. d'Amore F., Relander T., Lauritzsen G.F., et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012, 30:3093-3099.
20. Gkotzamanidou M., Papadimitriou C.A. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Crit Rev Oncol Hematol 2013, 10.1016/j.critrevonc.2013.08.016.
21. Skarbnik A.P., Burki M., Pro B. Peripheral T-cell lymphomas: a review of current approaches and hopes for the future. Front Oncol 2013, 3:138.
22. Armitage J.O. The aggressive peripheral T-cell lymphomas: 2013. Am J Hematol 2013, 88:910-918.
23. Czajczynska A., Gunther A., Repp R., et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2013, 19:1632-1637.
24. Kanakry J.A., Kasamon Y.L., Gocke C.D., et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013, 19:602-606.
25. Hale G.A., Shrestha S., Le-Rademacher J., et al. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012, 18:1036-1043. e1.
26. Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol 2010, 2010:320624.
27. Dearden C.E., Johnson R., Pettengell R., et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011, 153:451-485.
28. Savage K.J., Harris N.L., Vose J.M., et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008, 111:5496-5504.
29. Mosse Y.P., Lim M.S., Voss S.D., et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013, 14:472-480.
30. Suzuki R., Takeuchi K., Ohshima K., Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 2008, 26:66-72.
31. Yamaguchi M. Current and future management of NK/T-cell lymphoma based on clinical trials. Int J Hematol 2012, 96:562-571.
32. Li Y.X., Yao B., Jin J., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006, 24:181-189.
33. Yamaguchi M., Tobinai K., Oguchi M., et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol 2012, 30:4044-4046.
34. Aviles A., Cleto S., Castaneda C., Nambo M.J. CMED in the treatment of nasal natural killer cell lymphoma with distant metastases. Hematology 2007, 12:241-244.
35. Yamaguchi M., Suzuki R., Kwong Y.L., et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008, 99:1016-1020.
36. Kwong Y.L., Kim W.S., Lim S.T., et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012, 120:2973-2980.
37. Yamaguchi M., Kwong Y.L., Kim W.S., et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011, 29:4410-4416.
38. Jaccard A., Gachard N., Marin B., et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011, 117:1834-1839.
39. Yong W., Zheng W., Zhu J., et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors. Hematol Oncol 2006, 24:28-32.
40. Ferreri A.J., Zinzani P.L., Govi S., Pileri S.A. Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol 2011, 79:84-90.
41. Di Sabatino A., Biagi F., Gobbi P.G., Corazza G.R. How I treat enteropathy-associated T-cell lymphoma. Blood 2012, 119:2458-2468.
42. Sieniawski M., Angamuthu N., Boyd K., et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010, 115:3664-3670.
43. Al-toma A., Visser O.J., van Roessel H.M., et al. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood 2007, 109:2243-2249.
44. Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007, 110:2316-2323.
45. Marchi E, O'Connor OA. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol;3:227-35.
46. Marchi E, Mangone M, Zullo K, O'Connor OA. Pralatrexate pharmacology and clinical development. Clin Cancer Res. In press.
47. Wang E.S., O'Connor O., She Y., Zelenetz A.D., Sirotnak F.M., Moore M.A. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003, 44:1027-1035.
48. Toner L.E., Vrhovac R., Smith E.A., et al. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12:924-932.
49. Marchi E., Paoluzzi L., Scotto L., et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin Cancer Res 2010, 16:3648-3658.
50. O'Connor O.A., Horwitz S., Hamlin P., et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357-4364.
51. O'Connor O.A., Pro B., Pinter-Brown L., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29:1182-1189.
52. Damaj G., Gressin R., Bouabdallah K., et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013, 31:104-110.
53. Hassler M.R., Schiefer A.I., Egger G. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma. Epigenomics 2013, 5:397-415.
54. Piekarz R.L., Robey R.W., Zhan Z., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004, 103:4636-4643.
55. Piekarz R.L., Frye R., Prince H.M., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
56. Coiffier B. Monoclonal antibodies in the treatment of indolent lymphomas Best Pract Res Clin Haematol 2005, 18:69-80.
57. Dupuis J., Morschhauser F., Ghesquieres H., et al. A phase Ib/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP study. Hematol Oncol 2013, 31(Suppl 1):135. [abstract 18].
58. O'Connor O., Masszi T., Savage K., et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): results from the BELIEF trial. J Clin Oncol 2013, 31(Suppl). [abstract 8507].
59. Duvic M., Dummer R., Becker J.C., et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013, 49:386-394.
60. Piccaluga P.P., Agostinelli C., Righi S., Zinzani P.L., Pileri S.A. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007, 92:566-567.
61. Zinzani P.L., Corradini P., Gallamini A., et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012, 53:789-795.
62. Enblad G., Hagberg H., Erlanson M., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004, 103:2920-2924.
63. Kim J.G., Sohn S.K., Chae Y.S., et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007, 60:129-134.
64. Feld J., Barta S.K., Schinke C., Braunschweig I., Zhou Y., Verma A.K. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget 2013, 4:397-412.
65. Doronina S.O., Toki B.E., Torgov M.Y., et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003, 21:778-784.
66. Younes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
67. Pro B., Advani R., Brice P., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012, 30:2190-2196.
68. Subramaniam J.M., Whiteside G., McKeage K., Croxtall J.C. Mogamulizumab: first global approval. Drugs 2012, 72:1293-1298.
69. Yamamoto K., Utsunomiya A., Tobinai K., et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598.
70. Ishida T., Joh T., Uike N., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012, 30:837-842.
71. Ueda R., Ogura M., Ishida T., et al. The efficacy and safety of mogamulizumab (KW-0761) in multicentre phase II study for patients with relapsed peripheral or cutaneous T-cell lymphoma. Hematol Oncol 2013, 31(Suppl 1):109. [abstract 41].
72. Ishida T., Ito A., Sato F., et al. Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013, 104:647-650.
73. Kaminetzky D., Hymes K.B. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2008, 2:717-724.
74. Dang N.H., Pro B., Hagemeister F.B., et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136:439-447.
75. Foss F., Sjak-Shie N., Goy A., Advani R., Jacobsen E. Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. J Clin Oncol 2010, Suppl:15s:28. [abstract 8045].
76. Dueck G., Chua N., Prasad A., et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116:4541-4548.
77. Morschhauser F., Fitoussi O., Haioun C., et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 2013, 49:2869-2876.
78. Friedberg J.W., Mahadevan D., Cebula E., et al. Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 2014, 32:44-50.
79. Federico M., Rudiger T., Bellei M., et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project. J Clin Oncol 2013, 31:240-246.
80. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.